GLP-1 Receptor Agonists and Bowel Obstruction Risk

Introduction to GLP-1 Receptor Agonist Risks

GLP-1 receptor agonists are contraindicated in patients with active bowel obstruction and should be discontinued immediately if bowel obstruction is suspected or diagnosed, as recommended by the American Gastroenterological Association 1, 2

GLP-1 receptor agonists significantly delay gastric emptying, reducing phasic gastric contractions and increasing gastric volumes, which can worsen or precipitate bowel obstruction, particularly in patients with pre-existing gastrointestinal motility disorders, according to the American Gastroenterological Association 3

The American Society of Anesthesiologists identifies gastrointestinal obstruction as a condition that increases aspiration risk and requires clinical judgment when considering procedures in patients on GLP-1 receptor agonists, with a high-risk category similar to gastroparesis and previous gastric surgery 1, 2

The American Society of Anesthesiologists recommends immediately discontinuing the GLP-1 receptor agonist if bowel obstruction is suspected or diagnosed, regardless of indication 1, 2
The Anaesthesia society suggests documenting specific risk factors, including GLP-1 agent, dose, and last administration date, presence of nausea or vomiting, and co-prescribed medications that delay gastric emptying 4, 5
The American Gastroenterological Association advises assuming the stomach is full when planning procedural interventions requiring sedation or anesthesia in patients on GLP-1 receptor agonists 1, 2
The Anaesthesia society recommends implementing aspiration risk reduction strategies, including rapid sequence intubation, point-of-care gastric ultrasound, and pre-emptive gastric decompression in high-risk patients 4, 5

The Anaesthesia society warns against assuming standard fasting times are adequate, as retained gastric contents can occur despite 8-12 hour fasting periods in patients on GLP-1 receptor agonists 6, 7
The American Gastroenterological Association advises against relying on short discontinuation periods, as discontinuation for 7 days may not decrease the prevalence of retained gastric contents for long-acting agents 4, 5